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Results: The recombinant lentivirus plasmid carrying ZO-1 was correctly constructed,
it was identiﬁed correct by double enzyme digestion and DNA sequencing. The
lentiviral packaging was succeed, and the titer of lentivirus was 1.42108IU/ml.
Conclusion: Lenti-EF1a-EGFP-TRE-ZO1 lentiviral vector has been successfully
constructed. The titer of lentivirus was 1.42108IU/ml, it was used to infect iPS cells,
which will be useful for further study in vivo, to understand its function and its unique
effects under different pathological status of heart, and open new doors for the
treatment of cardiovascular diseases.
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Exogenous Hydrogen Sulﬁde Delays Nicotinamide-Induced Premature
Senescence via SIRT1 pathway in Human Umbilical Vein Endothelial Cells
Qiao Weili, Zheng Meihua, Liu Lei, Yan Changdong
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Objectives: The present study was designed to observe the effect of hydrogen sulﬁde
(H2S) on cellular senescence of human umbilical vascular endothelial cells (HUVECs
CC-2517) and its underlying mechanism.
Methods: The premature senescence-like phenotypeHUVECs (the fourth passage) was
induced by nicotinamide (NAM, an inhibitor of SIRT1) at the concentration of 5mmol/L
for 12 hours. Cells were cultured with sodium hydrosulﬁde (NaHS, 12.5, 25, 50,
100mmol/L) added into the fresh medium for 48 hours on the basis of premature
senescence-like phenotyoe HUVECs. The fourth passage of HUVECs was considered
as young group. Senescence associated (SA) -b-galactosidase activities were detected to
evaluate cell senescence, and the expression of senescence associated heterochromatin
foci (SAHF) was visualized by DAPI DNA staining. The mRNA and protein levels of
SIRT1 were detected using RT-PCR and western blotting analysis, respectively.
Results: The results showed that b-galactosidase positive cells and the formation of
SAHF were markedly increased after treatment with NAM (5mmol/L) for 12h. We also
found that NaHS (12.5mmol/L) had no effect on the percentage of SA b-gal positive cells
and the expression of SAHF, and the hallmarks decreased at the concentration of 25 and
50mmol/L, reaching the minimum at 50 mmol/L, while the percentage of SA b-gal
positive cells and the expression of SAHF increased at the concentration of 100mmol/L.
Furthermore we found that SIRT1 expression both on protein and mRNA in the
Y+N+S50 group was signiﬁcantly increased compared with that in Y+N group.
Conclusions: NaHS delays senescence of HUVECs induced by NAM via up-regu-
lation of SIRT1 expression.
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MicroRNAs and cardiac channelopathies
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Objectives: Cardiac channelopathies are primary arrhythmias caused by variations in
the genes encoding cardiac ion channels. It is one of the major causes which could
lead to sudden cardiac death.
Methods: The pathological change leading to cardiac channelopathies is intimately
linked to the geno-variations. MicroRNAs (miRNAs) are one of the participants that
regulate the target gene expression.
Results: Burgeoning evidences indicated that miRNAs are closely associated with
myocardial development, proliferation, differentiation, apoptosis and ion channel
remodeling, especially involved in arrhythmias, congenital heart disease, hyperten-
sion, and myocardial ischemia. In vivo and in vitro studies suggested that miRNAs
may serve as a diagnostic biomarker for cardiac channelopathies. They can modulate
the function of cardiac ion channel genes and would be a good choice to act as a
miRNA-based therapy method.
Conclusions:We review the mechanisms and functions of miRNAs related to cardiac
ion channels and focus on the potential perspective of miRNAs as a novel therapeutic
target for cardiac channelopathies.
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ZP2495 improves cardiomyocyte energy metabolism post myocardial
ischemia-reperfusion injury in db/db diabetic mice
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Objectives: This study was designed to evaluate the impact of a glucagon-GLP-1
dual-agonist (ZP2495) on cardiac function and energy metabolism after myocardial
ischemia-reperfusion injury in db/db mice, and the underlying mechanisms involved.
Methods: The peptides of glucagon, GLP-1 receptor agonist (ZP131) and glucagon-
GLP-1 dual-agonist (ZP2495) were synthesized and puriﬁed by ChinaPeptides. Wild-
type (WT) and db/db mice received 4-weeks treatment of glucagon, ZP131 or ZP2495
followed by left anterior descending coronary artery (LAD) ligation and reperfusion.
Cardiac function, hemodynamic parameters, glucose metabolism, myocardial infarct
size, cardiomyocyte apoptosis, mitochondrial ultrastructural morphology, mitochon-
drial respiration and ATP synthesis were measured. Mitochondrial membraneC44 JACC Vol 64/16/Suppl C j Octobpotential, mitochondrial cytochrome c release and mitochondria reactive oxygen
species (ROS) generation were assessed in high-glucose-induced neonatal rat ven-
tricular myocytes (NRVMs) after simulated ischemia/reperfusion (SI/R) injury. The
expressions of FoxO3a, phospho-FoxO3a (Thr32, Ser413), Akt, phospho-Akt
(Ser473, Thr308) AMPK, phospho-AMPK (Thr172), Bim, Bax, Bcl-2, Bad, phospho-
Bad, MnSOD, Catalase,Sirt1, PGC1a, Acetylated-Lysine, Nrf-1, Tfam of the heart
tissue were detected by Western blot.
Results: ZP2495 treatment improved cardiac function and cardiac glucose metabolism,
decreased apoptotic cardiomyocytes, improvedmitochondrial ultrastructural morphology
and mitochondrial energetic transition of db/db mice after cardiac I/R injury. ZP2495
treatment preventedmitochondrial depolarization and reduced the release of cytochrome c
and mitochondria reactive oxygen species (ROS) generation in high-glucose-induced
NRVMs after SI/R injury. Western blot revealed that ZP2495 exerted anti-apoptotic
and anti-oxidation effect on cardiomyocyte of db/db mice after cardiac I/R injury via
Akt/FoxO3a-dependent mechanism. In addition, ZP2495 improved energy metabolism
and increased mitochondrial biogenesis in hearts of db/db mice subjected to I/R injury
through AMPK/FoxO3a and AMPK-SIRT1-PGC-1a pathway.
Conclusions: Glucagon and GLP-1 dual-agonist (ZP2495) protects against myocar-
dial I/R injury in db/db mice, which may contribute to the improvement of cardiac
function and cardiac energy metabolism. The protective effects of ZP2495 may be
associated with the Akt/FoxO3a, AMPK/FoxO3a and AMPK-SIRT1-PGC-1a path-
ways activation.
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Statin attenuate cardiac hypertrophy by regulating autophagy via AKT/mTOR
Pathway in Spontaneously Hypertensive Rats
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Objectives: Autophagy is activated in hypertension-induced cardiac hypertrophy, in
which the mechanisms are not clear. Our previous study has demonstrated that ator-
vastatin inhibites heart remodeling spontaneously hypertensive rats (SHR). This study
was designed to determine the regulation of atorvastatin on cardiac autophagy in
SHRs.
Methods: Twenty-four male SHRs at 8 weeks of age were randomly divided into four
groups receiving vehicle (SHR+V) or atorstatin at a dose of 50 mg/kg/day
(SHR+ATO) until ages of 6 months or 12 months old. WKY rats were used as
controls. Cardiac magnetic resonance (CMR) was used to evaluate heart functions.
Autophagy was demonstrated by the up-regulated expression of microtubule-associ-
ated protein-1 light chain 3-II (LC3-II), Beclin-1, caspase-3, the formation of auto-
phagosomes, and by the electron microscopic ﬁndings. Western blot analysis shows
the expression of the proteins.
Results: Atorstatin treatments for both 4 and 10 months signiﬁcantly attenuated car-
diac dysfunction, remodeling, and atrial natriuretic peptide expression in SHRs, which
were increased compared with WKY rats. At 12 months of age, autophagy was found
to be activated in the heart of SHRs treated with vehicle or atorstatin. The activated
autophagy was especially increased in the cardiomyocytes of SHRs with atorstatin
treatment for 10 months. P-Akt and P-mTor decreased in the heart of SHR versusWKY
rats, while atorstatin further decreased cardiac akt and mTor phosphorylation.
Conclusions: These ﬁndings suggest that atorvastatin attenuated cardiac remodeling
and heart dysfunction in SHR probably through its regulation on cardiac autophagy
via akt/mTor pathways.
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Effects of EPC-derived Microvesicles on Ang II-induced Cardiomyocyte
Hypertrophy and Apoptosis
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Objectives: Cell-released microvesicles (MVs) are implicated in mediating cell-to-cell
communication and are able to modulate target cell functions. Previous evidence in-
dicates that endothelial progenitor cells (EPCs) -derived MVs can modulate endo-
thelial cell survival and proliferation. In this study, we evaluated whether EPC-MVs
could protect cardiomyocytes (CMs) against angiotensin II (Ang II) -induced hyper-
trophy and apoptosis.
Methods: The cell line H9c2 CMs were exposed to Ang II in the presence or absence
of EPC-MVs. Cell viability, apoptosis, surface area and b-myosin heavy chain
(b-MHC) expression were analyzed. To investigate the underlying mechanisms,
reactive oxygen species (ROS) generation, serine/threonine kinase (Akt), phospho-Akt
(P-Akt), endothelial nitric oxide synthase (eNOS) and phospho-eNOS (P-eNOS)
expression levels were measured. The inhibitors of phosphatidylinositol-3-kinase
(PI3K) and NOS were used for pathway veriﬁcation. The role of MV carried RNAs in
mediating these effects was also explored.
Results: Results showed: (1) EPC-MVs were able to protect CM against Ang II-in-
duced changes in cell viability, apoptosis, surface area and b-MHC expression;er 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
(2) These effects of EPC-MVs were accompanied with a reduction of ROS production,
which could be abolished or partially blocked by PI3K or NOS inhibitor, and with
protein up-regulations in Akt/P-Akt and its downstream eNOS/P-eNOS; (3) Depletion
of RNAs from EPC-MVs partially eliminated the protective effects of EPC-MVs.
Conclusions: Our data indicate that EPC-MVs can protect H9c2 CMs from Ang
II-induced hypertrophy and apoptosis through the activation of PI3K/Akt/eNOS
signaling pathway, at least partly via the mediation of the RNAs carried by them.
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Changes of transmural heterogeneity of CX43 expression in chronic heart failure
Zhong Jianghua, Lu Shijuan
Haikou People’s Hospital
Objectives: To observe transmural heterogeneity of ventricular repolarization and
CX43 protein in chronic heart failure (CHF), and electrophysiological and molecular
mechanisms of malignant ventricular arrhythmia (MVA) in the CHF.
Methods: All rabbits were randomly divided into CHF group which was made with
traditional abdominal aorta constriction method and sham operation group. Ventric-
ular ﬁbrillation threshold (VFT), 90% monophasic action potential repolarization
duration (APD90) of subepicardial, midmyocardial and subendocardial myocardium,
transmural dispersion of repolarization (TDR) and CX43 protein expression in three
layers of myocardium were measured in both groups.
Results: There was a signiﬁcant difference between the sham operation group and the
CHF group [(13.151.88) & (7.461.22) V, P<0.01]. APD90 of three myocardial
layers in the CHF group were signiﬁcantly prolonged more than those in the sham
operation group (P<0.01). DAPD90 and TDR in the CHF group were signiﬁcantly
higher than those in the sham operation group (P<0.05). CX43 protein expression of
all three myocardial layers were decreased obviously in the CHF group (P<0.05), but
reduction was more signiﬁcant in the midmyocardium.
Conclusions: Increased transmural heterogeneity of CX43 expression may enlarge
dispersion of repolarization across ventricular wall and easy to induce MVA in CHF.
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Activation of Liver X receptor attenuates OxLDL-induced endothelial
inﬂammation during atherosclerosis
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Objectives: The liver X receptors are ligand-dependent transcription factors that have
been implicated in the control of cholesterol and fatty acid metabolism as well as
macrophage inﬂammatory gene expression. Oxidized low-density lipoprotein induced
endothelial inﬂammation is the initial step during pathogenesis of atherosclerosis
which trigger the expression of adhesion molecular and the secretion of chemokine in
endothelial cell to recruitment of monocyte/macrophages. Although the ligand of liver
X receptor are known to regress atherosclerosis in mouse models, their ability to
control the endothelial inﬂammatory induced by OxLDL has not been addressed.
Methods: We evaluated the macrophage inﬁltration of aortic sinus in apoE-/- mice
intravenous injected with the ligand of liver X receptor GW3965 or control using
immunohistochemistry. HUVECs were treated with lysophosphatidylcholine (LPC), a
major chemotactic lipid component of oxLDL, after the incubation of GW3965 or
vehicle. The secretion of chemokine and the activity of NF-kB pathway were
measured by ELISA, Western Blot and the NF-kB (p65) Transcription Factor Assay
Kit. In addition, we also knocked down UBC9 and HDAC4, indispensable small
ubiquitin-like modiﬁer (SUMO) ligase, mediated by siRNA to evaluate the modiﬁ-
cation of SUMOylation in this suppression of liver X receptor.
Results: Fewer macrophages were present in the aortas of apoE-/- mice and the
quantitative analysis revealed signiﬁcantly less MOMA-2-positive staining in
GW3965 treatment group than in the control (P<0.05). And the levels of IL-8 in
supernatant of HUVECs at each time and concentration point were markly elevated in
the LPC treatment group relative to the Control (P<0.05), whereas signiﬁcant de-
creases (P<0.02) were observed in GW3965 and LPC treatment group. Western Blot
clearly revealed GW3965 decreased the phosphorylation of IKK-alpha/beta and IKB-
alpha. What’s more, the NF-kB (p65) Transcription Factor Assay Kit also indicated
GW3965 inhibited p65 binding to IL-8 gene promoters in LPC-stimulated HUVECs.
In addition, knockdown of UBC9 or HDAC4 abrogated the effects of GW3965 on
antagonizing LPC-induced IL-8 overexpression.
Conclusions: These ﬁndings suggest that the ligand of liver X receptor activates
SUMOylation and inhibits NF-kB activation in LPC-stimulated HUVECs, which in
turn decrease chemokines expression. The results unveil a new mechanism triggered
by liver X receptor for prevention of atherosclerosis.
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Expression of Connexin 43 in Non-culprit arteries and Role of Angiotensin II in
Expression of Connexin 43
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Beijing100029, China, 2Department of Cardiology, Qinghai Provincal People’s
Hospital, Xi-ning, Qinghai Province, 810007, ChinaJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BObjectives: To study expression of connexin 43 (Cx43) in Smooth muscle cells of
Non-culprit arteries and role of angiotensin II in expression of connexin 43.
Methods: Myocardial ischemia-reperfusion model in rabbit was prepared; ﬂuores-
cence immunohistochemistry analytical method was used to semiquantitative analysis
for Cx43 in Smooth muscle cells of non-infarction related arteries. Smooth muscle
cells in non-infarction related arteries were isolated and cultured, Smooth muscle cells
were divided into 4 groups (12 samples in each group) at random: (1) normal control
group. (2) Hyperlipidemia control group. (3) angiotensin II (Ang II) intervention
group: smooth muscle cells were stimulated with 110-7mol/L Ang II for 24 h. (4)
MARK signal transduction pathway inhibitor pretreatment and Ang II intervention
group:inhibitor (PD98059 (100mmol/L), SP600125 (25mmol/L), SB203580 (25mmol/
L) ) pretreatment for 30 min before the addition of Ang II for 24 h. Expression of
Cx43 in each group was analysised.
Results: Expression of Cx43 in hyperlipidemia control group was higher than that in
normal control group (1.250.21 vs 0.620.14, P<0.05); Expression of Cx43 in Ang
II intervention group was higher than that in hyperlipidemia control group (1.790.31
vs 1.250.21, P<0.05); Expression of Cx43 in MARK signal transduction pathway
inhibitor pretreatment and Ang II intervention group was lower than that in Ang II
intervention group[(0.850.19 vs 1.790.31, P<0.05), (0.990.13 vs 1.790.31,
P<0.05), (0.810.15 vs 1.790.31, P<0.05) respectively].
Conclusions: Expression of Cx43 in Smooth muscle cells of Non-culprit arteries may
be increase,and it may be involved in Ang II - MARK signal transduction pathway.
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Effects of rosuvastatin on vascular cell adhesion molecule-1 expression injured
by homocysteine in human umbilical vein endothelial cells
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Objectives: To study the effects of rosuvastatin on the expression of vascular cell
adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs)
injured by homocysteine (HCY).
Methods: The HUVECs were primary cultured. HUVECs from the second to fourth
generations were stimulated with different concentrations of HCY (range from
0.2mmol/lw1.2 mmol/l). The model of cell injury was set up with the concentration of
HCY 0.6mmol/l. Then the HUVECs were pretreated with rosuvastatin in different
concentration for 2 hours before HCY is added. The expression of VCAM-1 mRNA
was evaluated by real time-PCR. The content of VCAM-1 protein was detected with
western blot, and mevalonate (MEV) was added to evaluate whether the effect of
rosuvastatin on expression of VCAM-1 can be blocked.
Results: Hcy with concentration above 0.6mmol/L could effectively injure HUVECs
after 24 hours. Damage degree was dose dependent. Rosuvastatin with concentration
of 1.0mmol/L and 2.0mmol/L can effectively reverse the injury induced by 0.6mmol/
L Hcy. In HCY group, the content of VCAM-1 protein and the expression of VCAM-
1 mRNA was increased signiﬁcantly (P<0$05). In Rosuvastatin group, the content of
ICAM-1 protein and the mRNA expression of ICAM-1 was signiﬁcantly decreased
(P<0$05). The effects of Rosuvastatin on VCAM-1 protein can’t be blocked by
mevalonate.
Conclusions: Hcy can damage the HUVECs through the process of inﬂammation.
Rosuvastatin has shown the protective effect against the damage induced by Hcy
through the anti-inﬂammatory effect. Rosuvastatin have the function of anti-athero-
sclerosis by inhibiting the expression of ICAM-1 induced by HCY in HUVECs, and
the effect is independent on its lipid-lowering effect.
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rs3740835 Variant in Kcnj5 Gene Related to the CT Scan-Based Adrenal
Hyperplasia in Patients with Primary Aldsteronism
Yao Xiaoguang, Li Nanfang, Zhang Delian, Chang Guijuan, Zhou Keming, Luo Qin,
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Objectives: As a novel candidate gene contributing to primary aldosteronism (PA),
KCNJ5 gene is believed to play roles in adrenal hyperplasia. The present study aims to
explore the association of variants in KCNJ5 gene with CT scan-based adrenal hy-
perplasia in patients with PA from Xinjiang.
Methods: Followed the guideline of PA in 2008, a protocol for PA screening and
diagnosis was performed in Center of hypertension in Xinjiang from 2008 to 2010.
Finally, 457 cases of subjects with conﬁrmed PA were enrolled and were divided into
adrenal hyperplasia group and control group according to the ﬁndings of thin-section
CT scan. The blood samples were collected for DNA extraction and genotype
identiﬁcation.
Results: (1) The average level of plasma potassium in patients with adrenal hyperplasia
was (3.630.42) mmol/L, which was signiﬁcantly lower than that in controls
(3.760.37) mmol/L with P¼0.001. But the baseline plasma aldostrone level
(22.7826.52) ng/dl, urine potassium excretion (46.0222.47) mmol/L in the adrenal
hyperplasia group was higher than those in controls, which was (18.137.60) ng/dl,
P¼0.032) and (42.3715.66) mmol/L, P¼0.080). The age, mean blood pressure, body
mass index, plasma sodium, urine sodium excretion as well as plasma rennin activity
was matched. (2) 41.3% subjects were diagnosed as obstructive sleep apnea syndrome,asic and Translational Medicine C45
